S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.85 (+1.79%)
AAPL   143.23 (+4.10%)
MSFT   260.96 (+3.33%)
FB   196.30 (+1.43%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,153.50 (+0.08%)
TSLA   675.00 (+1.67%)
NVDA   169.60 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.39 (+2.02%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.76 (+1.76%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.69 (-2.83%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.85 (+1.79%)
AAPL   143.23 (+4.10%)
MSFT   260.96 (+3.33%)
FB   196.30 (+1.43%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,153.50 (+0.08%)
TSLA   675.00 (+1.67%)
NVDA   169.60 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.39 (+2.02%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.76 (+1.76%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.69 (-2.83%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.85 (+1.79%)
AAPL   143.23 (+4.10%)
MSFT   260.96 (+3.33%)
FB   196.30 (+1.43%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,153.50 (+0.08%)
TSLA   675.00 (+1.67%)
NVDA   169.60 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.39 (+2.02%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.76 (+1.76%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.69 (-2.83%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.85 (+1.79%)
AAPL   143.23 (+4.10%)
MSFT   260.96 (+3.33%)
FB   196.30 (+1.43%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,153.50 (+0.08%)
TSLA   675.00 (+1.67%)
NVDA   169.60 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.39 (+2.02%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.76 (+1.76%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.69 (-2.83%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Forecast, Price & News

$0.20
+0.02 (+10.72%)
(As of 05/23/2022 03:59 PM ET)
Add
Compare
Today's Range
$0.18
$0.21
50-Day Range
$0.14
$0.33
52-Week Range
$0.13
$1.67
Volume
6,241 shs
Average Volume
565,444 shs
Market Capitalization
$15.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.42
30 days | 90 days | 365 days | Advanced Chart
Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Soleno Therapeutics logo

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLNO
Employees
17
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.33 per share

Profitability

Net Income
$-30.91 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
65,913,000
Market Cap
$15.96 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/31/2022
Today
5/23/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

888th out of 1,416 stocks

Electromedical Equipment Industry

14th out of 29 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 283,400 shares, a decline of 25.5% from the April 15th total of 380,300 shares. Based on an average trading volume of 669,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.4% of the company's stock are sold short.
View Soleno Therapeutics' Short Interest
.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Soleno Therapeutics
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its earnings results on Thursday, March, 31st. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08).
View Soleno Therapeutics' earnings history
.

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics shares reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

Who are Soleno Therapeutics' key executives?
Soleno Therapeutics' management team includes the following people:
  • Dr. Anish Bhatnagar, Pres, CEO, COO & Director (Age 52, Pay $756k)
  • Mr. James H. MacKaness, Chief Financial Officer (Age 58, Pay $198.99k) (LinkedIn Profile)
  • Mr. Anthony Wondka, Sr. VP & GM (Age 60)
  • Dr. Neil M. Cowen M.B.A., Ph.D., MBA, Sr. VP of Drug Devel.
What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (11.78%), AIGH Capital Management LLC (8.49%), Granite Point Capital Management L.P. (3.30%), Worth Venture Partners LLC (2.11%), Empery Asset Management LP (1.75%) and Renaissance Technologies LLC (0.31%). Company insiders that own Soleno Therapeutics stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness and William G Harris.
View institutional ownership trends for Soleno Therapeutics
.

Which major investors are selling Soleno Therapeutics stock?

SLNO stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, and Simplex Trading LLC. Company insiders that have sold Soleno Therapeutics company stock in the last year include Bhatnagar Anish, and Jack W Schuler.
View insider buying and selling activity for Soleno Therapeutics
or view top insider-selling stocks.

Which major investors are buying Soleno Therapeutics stock?

SLNO stock was acquired by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Granite Point Capital Management L.P., Worth Venture Partners LLC, Empery Asset Management LP, and Renaissance Technologies LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Jack W Schuler, and James H Mackaness.
View insider buying and selling activity for Soleno Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $0.20.

How much money does Soleno Therapeutics make?

Soleno Therapeutics has a market capitalization of $15.96 million. The company earns $-30.91 million in net income (profit) each year or ($0.350010) on an earnings per share basis.

How many employees does Soleno Therapeutics have?

Soleno Therapeutics employs 17 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 213-8444, via email at [email protected], or via fax at 650-213-8383.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.